<DOC>
	<DOCNO>NCT00046930</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Zosuquidar trihydrochloride , modulator multidrug resistance ( MDR ) , may help daunorubicin cytarabine kill cancer cell make cancer cell sensitive drug . It yet know whether daunorubicin cytarabine effective without zosuquidar trihydrochloride treat acute myeloid leukemia anemia . PURPOSE : This randomized phase III trial study well give zosuquidar trihydrochloride together daunorubicin cytarabine work compare daunorubicin cytarabine alone treat old patient newly diagnose acute myeloid leukemia anemia respond previous treatment .</brief_summary>
	<brief_title>Daunorubicin &amp; Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Refractory Anemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival progression-free survival elderly patient newly diagnose acute myeloid leukemia , refractory anemia excess blast ( RAEB ) transformation , high-risk RAEB treat daunorubicin cytarabine without zosuquidar trihydrochloride . - Compare complete remission rate patient treat regimen . - Compare toxicity regimens patient . - Compare systemic exposure daunorubicin cytarabine patient treat zosuquidar trihydrochloride v placebo . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord age ( 60-69 year v 70 year ) , disease ( refractory anemia excess blast [ RAEB ] v RAEB transformation acute myeloid leukemia [ AML ] ) , disease type ( de novo v secondary ) . Patients randomize 1 2 treatment arm . - Induction : - Arm I : Patients receive daunorubicin via intravenous ( IV ) infusion 10-15 minute zosuquidar trihydrochloride IV 6 hour day 1-3 . Patients also receive cytarabine IV continuously day 1-7 . - Arm II : Patients receive daunorubicin cytarabine arm I . Patients also receive placebo IV 6 hour day 1-3 . Beginning day 12 , patient achieve aplasia receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously ( SC ) IV daily blood count recover . Patients evidence persistent AML eligible receive second identical course induction chemotherapy . - Consolidation I ( begin within 8 week documentation complete remission [ CR ] measurable remission [ MR ] ) : Patients achieve CR MR receive cytarabine IV 1 hour twice daily day 1-6 GM-CSF G-CSF SC IV begin day 7 continue blood count recover . - Consolidation II : Patients maintain peripheral blood evidence remission receive daunorubicin , cytarabine , zosuquidar trihydrochloride placebo induction chemotherapy . Patients also receive GM-CSF G-CSF SC IV begin day 8 last cytarabine dose continue blood count recover . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : Approximately 450 patient ( 225 per treatment arm ) accrue 4.1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>One follow disorder : Acute myeloid leukemia ( AML ) , define &gt; 30 % myeloblast marrow aspirate peripheral blood differential FrenchAmericanBritish ( FAB ) subtype except M3 ( i.e. , acute promyelocytic leukemia ) Refractory anemia excess blast ( RAEB ) , defined 1120 % myeloblasts bone marrow aspirate peripheral blood differential , provide criterion highrisk disease Refractory anemia excess blast transformation ( RAEBT ) , defined 2130 % myeloblasts bone marrow aspirate peripheral blood differential Participants may secondary AML Age great 60 year ECOG performance status 0 3 Total serum bilirubin &lt; 3 mg/dL Serum creatinine &lt; 2 mg/dL Cardiac ejection fraction &gt; 45 % Blastic transformation chronic myelogenous leukemia CNS leukemia Prior chemotherapy AML , exception hydroxyurea For woman : pregnant breast feed Other malignancy participant currently receive treatment Concurrent treatment colonystimulating factor</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>